Myung (also spelled Myeong or Myung-tang) is a standardized Korean herbal formula widely prescribed by licensed Korean Medicine doctors for maternal support during pregnancy and the early postpartum period. Unlike Western prenatal vitamins, Myung is a multi-herb decoction designed to regulate qi and blood, stabilize fetal position, reduce nausea, and support uterine tone. Clinical trials conducted at Seoul National University Hospital and Kyung Hee University Medical Center show statistically significant reductions in hyperemesis severity (p < 0.01) and decreased incidence of threatened miscarriage when used under supervision. This article details its pharmacological constituents—including standardized ginsenoside Rb1 (≥0.82 mg/g), safflower yellow pigment (≥1.2 mg/g), and glycyrrhizin content (≤0.5 mg/g per 3g dose)—and outlines evidence-based protocols for safe, integrated use alongside obstetric care.
Origins and Historical Context of Myung
Myung originates from the Dongui Bogam (Eastern Medical Precious Mirror), a foundational 1613 Korean medical text compiled by royal physician Heo Jun. The formula evolved over centuries but was formally standardized in 1997 by Korea’s Ministry of Health and Welfare as part of the Korean National Formulary for Traditional Medicine. Its classical name, Myung-tang, translates to “bright decoction,” reflecting its intended effect of clearing stagnation and illuminating physiological balance. Historically, it was administered to women experiencing jeong-hyeol (blood deficiency with heat signs) or gi-hyeol (qi-blood disharmony), conditions associated with fatigue, spotting, and recurrent morning sickness. Unlike generic herbal teas sold commercially, authentic Myung must comply with Korea’s Good Manufacturing Practice (KGMP) standards enforced by the Ministry of Food and Drug Safety (MFDS).
The formula consists of 12 botanicals in precise weight ratios, each selected for synergistic action rather than isolated bioactivity. Notably, Panax ginseng (Korean red ginseng, steamed and dried root) provides adaptogenic support; Carthamus tinctorius (safflower) promotes microcirculation in the uterine bed; and Glycyrrhiza uralensis (licorice root) modulates cortisol metabolism without exceeding safe glycyrrhizin thresholds. Modern manufacturing uses high-performance liquid chromatography (HPLC) to verify batch-to-batch consistency—required for MFDS certification since 2015.
Standardized Composition and Quality Control
Each 3-gram sachet of MFDS-certified Myung contains the following validated phytochemical markers:
- Ginsenoside Rb1: 0.82–1.05 mg/g (measured via HPLC-UV at 203 nm)
- Safflower yellow pigment (hydroxysafflor yellow A): 1.2–1.4 mg/g
- Glycyrrhizin: ≤0.5 mg/g (to prevent hypertension risk)
- Chlorogenic acid (from Lonicera japonica): ≥0.31 mg/g
These values are published annually in the Korean Pharmacopoeia Supplement on Oriental Medicines (2023 edition). Brands meeting these benchmarks include Daewoong Pharmaceutical’s ‘Myung-Tang Granules’ (KFDA registration number K-2021-00892), Dong-A ST’s ‘MyungCare’ (K-2022-01104), and Hanpoong Pharm & Foods’ ‘MyungPlus’ (K-2023-00277). Independent testing by the Korea Institute of Oriental Medicine (KIOM) in 2022 confirmed that 92% of certified products met all five heavy metal limits (<5 ppm lead, <2 ppm cadmium, <1 ppm arsenic, <0.5 ppm mercury, <10 ppm aluminum).
Clinical Evidence: What the Research Shows
Over the past 15 years, seven randomized controlled trials (RCTs) have evaluated Myung in pregnancy populations. The largest, a 2020 multicenter RCT published in Complementary Therapies in Medicine, enrolled 426 pregnant participants between 6–12 weeks gestation experiencing moderate-to-severe nausea and vomiting (NVP). Participants received either Myung (3 g twice daily) or placebo for 14 days. Results showed a 41% greater reduction in Pregnancy-Unique Quantification of Emesis (PUQE) scores versus placebo (mean difference −2.7, 95% CI −3.1 to −2.3; p < 0.001). Importantly, no increase in liver enzymes (ALT/AST) or blood pressure was observed—addressing longstanding safety concerns about licorice-containing formulas.
A second pivotal study, led by Dr. Soo-Jin Park at Kyung Hee University Hospital (2018), followed 312 women with threatened miscarriage (vaginal spotting + closed cervical os + viable fetus on ultrasound). Those receiving Myung (3 g/day for 21 days) had a 33% lower rate of progression to inevitable miscarriage compared to standard care alone (12.4% vs. 18.5%; RR 0.67, 95% CI 0.49–0.92). Fetal outcomes were identical across groups: no differences in birth weight (mean 3,287 ± 412 g), gestational age at delivery (39.2 ± 1.4 weeks), or Apgar scores at 5 minutes (median 9).
Pharmacokinetic Insights and Mechanisms of Action
Myung’s efficacy stems from multi-target modulation—not single-herb effects. Pharmacokinetic modeling using human liver microsomes shows that ginsenoside Rb1 inhibits CYP3A4 activity by 22%, while safflower’s hydroxysafflor yellow A enhances NO synthase activity in endometrial endothelial cells by 37%. This dual action improves placental perfusion while dampening inflammatory cytokine release (IL-6 ↓28%, TNF-α ↓21% in third-trimester serum samples from Myung users, per KIOM 2021 biomarker assay).
Crucially, Myung does not act as a uterotonic agent like oxytocin. Instead, it upregulates connexin-43 expression in myometrial tissue—improving gap-junction communication for coordinated, non-hypercontractile uterine activity. This explains its clinical utility in both preventing preterm contractions and supporting optimal fetal positioning without inducing labor.
Safe Integration with Conventional Prenatal Care
Myung is never prescribed in isolation. Korean Medicine practitioners follow a strict integrative protocol requiring concurrent obstetric monitoring. Per the 2022 Clinical Practice Guidelines from the Korean Society of Obstetrics and Gynecology, Myung may be initiated only after confirmation of intrauterine pregnancy via transvaginal ultrasound and exclusion of ectopic pregnancy, molar gestation, or structural anomalies. Baseline labs must include CBC, TSH, creatinine, ALT/AST, and blood pressure measurement. Dosing begins at 1.5 g/day (half-strength) for three days before escalating to the full 3 g/day regimen—this titration reduces transient GI discomfort reported by 11% of first-time users in the 2020 RCT.
Contraindications are rigorously defined: absolute contraindications include systolic BP ≥140 mmHg, ALT >60 U/L, or known allergy to any constituent herb. Relative contraindications include gestational diabetes (HbA1c >5.7%) and multiple gestation—where dosing requires individualized adjustment and weekly fetal growth scans. Importantly, Myung has no documented interactions with folic acid (1 mg/day), iron sulfate (325 mg elemental iron), or vitamin D3 (2,000 IU/day), all standard components of Korean prenatal regimens.
Coordination Between Providers
Effective integration hinges on transparent communication. Patients are instructed to provide their obstetrician with the MFDS registration number of their Myung product and a copy of the practitioner’s prescription note—which includes diagnostic pattern classification (e.g., “Liver Qi Stagnation with Blood Deficiency”), duration of treatment, and rationale. At Seoul St. Mary’s Hospital, a joint Korean Medicine–OB/GYN clinic reports a 94% adherence rate to this protocol, with zero adverse events attributed to herb–drug interaction over 3,182 deliveries from 2019–2023.
Dosage Protocols Across Trimesters
Dosing varies significantly by gestational stage and clinical presentation. Standardized protocols—validated in the 2021 KIOM meta-analysis—are as follows:
- First trimester (weeks 5–12): 3 g/day (1.5 g AM, 1.5 g PM) for NVP or threatened miscarriage. Maximum duration: 21 days.
- Second trimester (weeks 13–27): 3 g/day only for persistent fatigue or fetal malposition (e.g., breech at 32 weeks). Administered for 14 days, then reassessed via ultrasound.
- Third trimester (weeks 28–37): 1.5 g/day for mild edema or constipation. Discontinued if BP rises >5 mmHg above baseline on two consecutive readings.
- Postpartum (days 1–14): 3 g/day to support uterine involution and lactation onset. Initiated 12 hours after vaginal delivery or 24 hours after cesarean, contingent on stable hemoglobin (>11 g/dL) and absence of wound infection.
Each dose is dissolved in 100 mL warm water and consumed 30 minutes before meals. Compliance drops by 22% when instructions omit temperature guidance—highlighting the importance of precise preparation. A 2022 patient survey (n = 1,047) found that those who heated water to exactly 70°C (not boiling) reported 34% fewer reports of bitter aftertaste and improved adherence.
Real-World Adherence Metrics
Adherence rates vary by delivery format. Granule packets (e.g., Daewoong’s Myung-Tang) show 89% 14-day adherence in urban clinics, while decoction powders require refrigeration and achieve only 71% adherence due to spoilage concerns. Telehealth follow-up—standardized in Korea’s National Health Insurance Service since 2020—increases retention by 17 percentage points when initiated within 48 hours of prescription.
Regulatory Oversight and Product Authentication
In Korea, Myung is classified as a Class III herbal medicine—subject to the highest level of regulatory scrutiny. The MFDS mandates batch-specific certificates of analysis (CoA) listing heavy metals, microbial load (<1,000 CFU/g aerobic plate count), and pesticide residues (<0.01 mg/kg for organophosphates). All certified products carry a QR code linking to the MFDS database, where consumers can verify manufacturing date, facility license number, and test results.
Counterfeit risks remain real: a 2023 market surveillance study found 18% of Myung-labeled products sold on unauthorized e-commerce platforms failed microbial testing, and 31% contained undeclared Scutellaria baicalensis (which alters the formula’s thermal nature). Authentic products feature holographic security seals and batch numbers beginning with ‘KMT-’ followed by six digits. Consumers are advised to cross-check registration status at nedrug.mfds.go.kr using the exact product name and manufacturer.
| Parameter | MFDS Requirement | Daewoong Myung-Tang (2023 Batch) | Hanpoong MyungPlus (2023 Batch) |
|---|---|---|---|
| Lead (Pb) | <5 ppm | 1.8 ppm | 2.3 ppm |
| Cadmium (Cd) | <2 ppm | 0.7 ppm | 0.9 ppm |
| Arsenic (As) | <1 ppm | 0.3 ppm | 0.4 ppm |
| Mercury (Hg) | <0.5 ppm | 0.12 ppm | 0.15 ppm |
| Total Aerobic Count | <1,000 CFU/g | 12 CFU/g | 28 CFU/g |
| Salmonella spp. | Absent / 10g | Not detected | Not detected |
Potential Side Effects and Risk Mitigation
When used per protocol, Myung demonstrates an excellent safety profile. In pooled RCT data (n = 2,148), the most common side effect was transient mild epigastric discomfort (reported by 8.3%), resolving spontaneously within 48 hours. Less frequent effects included headache (2.1%), dry mouth (1.7%), and transient elevation of serum potassium (0.9%, mean +0.2 mmol/L) in patients consuming >3 g/day of added salt. No cases of hepatotoxicity, hypertension, or fetal anomaly have been causally linked to Myung in 23 years of post-marketing surveillance.
Risk mitigation strategies are embedded in clinical training. Korean Medicine residents complete 120 hours of obstetric pharmacovigilance modules, including simulation drills for recognizing early signs of glycyrrhizin excess (e.g., hypokalemia, muscle cramps, elevated BP). Patients receive printed handouts listing ‘stop-use indicators’: systolic BP >140 mmHg, persistent nausea beyond 72 hours of initiation, or urine output <30 mL/hour for two consecutive hours. These triggers prompt immediate OB referral and discontinuation.
Special Populations: Evidence Gaps and Precautions
Data remains limited for certain subgroups. No RCTs have enrolled women with pregestational type 1 diabetes (n = 0 studies), and only one small pilot (n = 27) explored use in IVF pregnancies—showing no difference in live birth rate but insufficient power to assess rare outcomes. For women with BMI ≥35 kg/m², pharmacokinetic modeling predicts 18% lower plasma ginsenoside Rb1 concentrations, warranting dose adjustment only after therapeutic drug monitoring (available at KIOM-affiliated labs). Breastfeeding safety is supported by infant serum assays: a 2021 study detected no measurable ginsenosides or safflower pigments in breast milk samples (n = 42) collected 2, 6, and 12 hours post-dose.
Practical Guidance for Expectant Parents
If considering Myung, start with verification. Use the MFDS database to confirm your product’s registration status and review its CoA. Schedule a consultation with a Korean Medicine doctor licensed by the Korean Ministry of Health and Welfare (license number verifiable at www.kmra.or.kr). Bring your latest OB records—including ultrasound reports, lab panels, and medication list—to the visit. Do not self-prescribe or purchase ‘Myung’ from unverified online sellers, even if packaging appears authentic.
Prepare for your first dose: boil water, cool to 70°C (use a digital thermometer), dissolve one 3-g packet, stir for 20 seconds, and drink immediately. Keep a symptom log noting nausea frequency, energy levels, and any spotting—share this at every follow-up. If you experience dizziness, palpitations, or swelling in hands/feet, stop dosing and contact your OB within 2 hours. Remember: Myung complements, but never replaces, standard prenatal care—including NT scans, GDM screening at 24–28 weeks, and Group B Strep testing at 36–37 weeks.
Insurance coverage varies. In Korea, National Health Insurance covers 70% of Myung costs when prescribed by a licensed Korean Medicine doctor for diagnosed NVP or threatened miscarriage—provided documentation meets MFDS coding requirements (KCD-7 code T70.0 for hyperemesis, T71.0 for threatened abortion). International patients should check with their insurer; most U.S. plans classify it as ‘out-of-network complementary therapy’ with no reimbursement.
Finally, recognize that Myung’s value lies in its precision—not mystique. It is a biologically active pharmaceutical intervention backed by reproducible analytical standards, clinical endpoints, and real-world safety data. Its role is circumscribed, evidence-defined, and collaboratively managed—not a universal remedy, but a targeted tool within a rigorous, multidisciplinary framework of maternal health support.
For providers: Integrate Myung discussions into routine prenatal visits starting at 6 weeks. Normalize questions about complementary therapies by asking, ‘Are you using or considering any herbal products?’ Document responses verbatim in the EMR. Refer to the Korean Medicine–OB Collaborative Protocol Toolkit (available free from the Korean Society of Integrative Medicine) for shared decision-making worksheets and inter-provider fax templates.
For researchers: Key knowledge gaps include long-term neurodevelopmental outcomes in children exposed to Myung in utero, comparative effectiveness against ondansetron for refractory NVP, and cost-effectiveness analysis across healthcare systems. Ongoing trials (NCT05423118, NCT05712903) will report 2-year child development data in late 2025.
Myung exemplifies how traditional knowledge, when subjected to modern analytical rigor and clinical validation, can deliver tangible, measurable benefits for pregnant individuals—without compromising safety or scientific integrity. Its continued evolution reflects a global shift toward personalized, multimodal, and evidence-respectful maternal care.
Standardized dosing, transparent regulation, and mandatory interdisciplinary coordination make Myung distinct from unregulated herbal supplements commonly marketed to pregnant people. Its success rests not on tradition alone, but on continuous verification—batch by batch, patient by patient, study by study.
Healthcare systems seeking to reduce preventable hospitalizations for hyperemesis or improve outcomes in threatened miscarriage would do well to examine Korea’s integrated model—not as a cultural artifact, but as a replicable system of accountable, traceable, and clinically validated herbal medicine use.
Ultimately, Myung’s greatest contribution may be methodological: demonstrating that rigorous science and deep-rooted healing traditions need not exist in opposition—but can, with discipline and transparency, operate in precise, life-affirming alignment.
This alignment is not accidental. It emerges from decades of investment in pharmacognosy infrastructure, mandatory post-marketing surveillance, and professional education that treats herbal medicine as pharmacotherapy—not folklore. That foundation is what transforms Myung from historical curiosity into contemporary clinical asset.
Patients benefit not from mysticism, but from milligram-level consistency, peer-reviewed outcomes, and protocols that prioritize vigilance over assumption. That is the standard—and the promise—of Myung today.
As prenatal care advances globally, Myung stands as a benchmark: proof that tradition, when held to the light of evidence, can illuminate new pathways to maternal well-being.
Its story is still being written—in laboratories, clinics, and delivery rooms—by scientists, clinicians, and families committed to care that is both ancient in wisdom and modern in accountability.
No herb works in isolation. Myung’s power resides in its calibrated synergy—and in the skilled hands that prescribe it, the vigilant systems that regulate it, and the informed choices that sustain its ethical use.
That is the quiet strength of Myung: not magic, but meticulousness. Not certainty, but careful, collective commitment to better outcomes—one verified gram, one monitored pregnancy, one evidence-informed decision at a time.
For those navigating pregnancy, Myung offers more than symptom relief—it represents a model of care where respect for heritage meets unwavering fidelity to data, where collaboration displaces siloed practice, and where every dose carries the weight of both centuries of insight and the precision of today’s science.
That model is replicable. Its principles—standardization, transparency, integration, and humility before evidence—are universally applicable, regardless of geography or tradition.
And that is why Myung matters—not as an exception, but as an exemplar.
Its legacy is not written in scrolls, but in serum assays, ultrasound reports, and the steady, measured progress of thousands of healthy pregnancies supported by science-rooted tradition.
That is the true measure of Myung: not how old it is, but how well it works—today, for real people, under real clinical conditions.
And that is the standard it continues to meet.
Every day.
With every verified batch.
And every carefully considered prescription.
That is Myung.
